4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL...
FDA Drug Recall #D-0620-2025 — Class II — July 30, 2025
Recall Summary
| Recall Number | D-0620-2025 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 30, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Exela Pharma Sciences LLC |
| Location | Lenoir, NC |
| Product Type | Drugs |
| Quantity | N/A |
Product Description
4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL Single Dose Vial, Rx Only, Manufactured and Distributed by: Exela Pharma Sciences, LLC, Lenoir, NC 28645 USA, NDC 51754-5012-1 (vial); 51754-5012-4 (carton)
Reason for Recall
Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot # 10004077, Exp. 02/28/2026
Other Recalls from Exela Pharma Sciences LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0303-2025 | Class II | 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/... | Mar 7, 2025 |
| D-0118-2024 | Class I | ELCYS (cysteine hydrochloride injection), USP, ... | Oct 18, 2023 |
| D-0116-2024 | Class I | 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/... | Oct 18, 2023 |
| D-0117-2024 | Class I | Midazolam in 0.8% Sodium Chloride Injection 100... | Oct 18, 2023 |
| D-0080-2023 | Class I | 8.4% Sodium Bicarbonate Injection, USP 50 mEq/5... | Nov 28, 2022 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.